Surgical treatment for diabetic macular edema

References

• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–136.
   PubMed Web of Science ®Google Scholar
• Roodhooft JM. Leading causes of blindness worldwide. Bull Soc Belge Ophtalmol. 2002;283:19–25.
   PubMedGoogle Scholar
• Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Res. 2012;47:171–188.
   PubMed Web of Science ®Google Scholar
• IDF diabetes atlas. 5th ed. Brussels: International Diabetes Federation; 2011.
   Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diabetes action now: an initiative of the World Health Organization and the International Diabetes Federation. Switzerland: World Health Organization; 2004.
   Google Scholar
• Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60:428–431.
   PubMed Web of Science ®Google Scholar
• Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003;5:12–21.
   PubMedGoogle Scholar
• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.
   PubMedGoogle Scholar
• Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375–1394.
   PubMed Web of Science ®Google Scholar
• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.. Arch Ophthalmol. 1985;103:1796–1806.
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102:7–16.
   PubMed Web of Science ®Google Scholar
• White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes. 2010;59:1244–1253.
   PubMed Web of Science ®Google Scholar
• Jones CD, Greenwood RH, Misra A, et al. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592–596.
   PubMed Web of Science ®Google Scholar
• Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12:346–354.
   PubMed Web of Science ®Google Scholar
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–389.
   PubMed Web of Science ®Google Scholar
• Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology. 2014;121:2443–2451.
   PubMed Web of Science ®Google Scholar
• Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina. 2006;26:562–570.
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–2405.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–625.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–2151.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Qin H, et al.; Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119:2312–2318.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–381.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904–1914.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117:1393–1399.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016. Epub ahead of print.
   Google Scholar
• Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753–759.
   PubMed Web of Science ®Google Scholar
• Panozzo G, Parolini B, Gusson E, et al. Diabetic macular edema: an OCT-based classification. Semin Ophthalmol. 2004;19:13–20.
   PubMedGoogle Scholar
• Massin P, Duguid G, Erginay A, et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol. 2003;135:169–177.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Riemann CD, Sears JE, et al. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol. 2001;131:44–49.
   PubMed Web of Science ®Google Scholar
• Ghazi NG, Ciralsky JB, Shah SM, et al. Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface. Am J Ophthalmol. 2007;144:747–754.
   PubMed Web of Science ®Google Scholar
• Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95:1335–1339.
   PubMed Web of Science ®Google Scholar
• Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473–478.
   PubMed Web of Science ®Google Scholar
• Muqit MMK, Stanga PE. Swept-source optical coherence tomography imaging of the cortical vitreous and the vitreoretinal interface in proliferative diabetic retinopathy: assessment of vitreoschisis, neovascularisation and the internal limiting membrane. Br J Ophthalmol. 2014;98:994–997.
   PubMed Web of Science ®Google Scholar
• Gandorfer A, Rohleder M, Grosselfinger S, et al. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol. 2005;139:638–652.
   PubMed Web of Science ®Google Scholar
• Agarwal D, Gelman R, Prospero Ponce C, et al. The vitreomacular interface in diabetic retinopathy. J Ophthalmol. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690–1696.
   PubMed Web of Science ®Google Scholar
• Golan S, Loewenstein A. Surgical treatment for macular edema. Semin Ophthalmol. 2014;29:242–256.
   PubMed Web of Science ®Google Scholar
• Stefánsson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435–440.
   PubMedGoogle Scholar
• Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye (Lond). 2008;22:1337–1341.
   PubMed Web of Science ®Google Scholar
• Stolba U, Binder S, Gruber D, et al. Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol. 2005;140:295–301.
   PubMed Web of Science ®Google Scholar
• Thomas D, Bunce C, Moorman C, et al. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol. 2005;89:81–86.
   PubMed Web of Science ®Google Scholar
• Patel JI, Hykin PG, Schadt M, et al. Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye (Lond). 2006;20:873–881.
   PubMed Web of Science ®Google Scholar
• Yanyali A, Horozoglu F, Celik E, et al. Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol. 2006;16:573–581.
   PubMed Web of Science ®Google Scholar
• Yanyali A, Nohutcu AF, Horozoglu F, et al. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol. 2005;139:795–801.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sinha S, Azad R, et al. Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2007;245:360–368.
   PubMed Web of Science ®Google Scholar
• Simunovic MP, Hunyor AP, Ho I-V. Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol. 2014;49:188–195.
   PubMed Web of Science ®Google Scholar
• Gandorfer A, Messmer EM, Ulbig MW, et al. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126–133.
   PubMed Web of Science ®Google Scholar
• Hoerauf H, Brüggemann A, Muecke M, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2011;249:997–1008.
   PubMed Web of Science ®Google Scholar
• Bardak Y, Cekiç O, Tiğ SU. Comparison of ICG-assisted ILM peeling and triamcinolone-assisted posterior vitreous removal in diffuse diabetic macular oedema. Eye (Lond). 2006;20:1357–1359.
   PubMed Web of Science ®Google Scholar
• Bahadir M, Ertan A, Mertoğlu O. Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol. 2005;26:3–8.
   PubMedGoogle Scholar
• Kumagai K, Hangai M, Ogino N, et al. Effect of internal limiting membrane peeling on long-term visual outcomes for diabetic macular edema. Retina. 2015;35:1422–1428.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Roggia MF, Noda Y, et al. Effect of internal limiting membrane peeling during vitrectomy for diabetic macular edema: systematic review and meta-analysis. Retina. 2015;35:1719–1725.
   PubMed Web of Science ®Google Scholar
• Romano MR, Romano V, Vallejo-Garcia JL, et al. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema. Retina. 2014;34:1182–1189.
   PubMed Web of Science ®Google Scholar
• Lee DH, Kim YJ, Yoon YH. Minimally invasive microincision vitrectomy surgery with an intraoperative dexamethasone implant for refractory diabetic macular edema. Ophthalmologica. 2016;235:150–156.
   PubMed Web of Science ®Google Scholar
• Bonnin S, Sandali O, Bonnel S, et al. Vitrectomy with internal limiting membrane peeling for tractional and nontractional diabetic macular edema: long-term results of a comparative study. Retina. 2015;35:921–928.
   PubMed Web of Science ®Google Scholar
• Navarrete-Sanchis J, Zarco-Bosquets J, Tomas-Torrent JM, et al. Long-term effectiveness of vitrectomy in diabetic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2015;253:713–719.
   PubMed Web of Science ®Google Scholar
• Adelman R, Parnes A, Michalewska Z, et al. Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. Biomed Res Int. 2015;2015:352487.
   PubMed Web of Science ®Google Scholar
• Haller JA, Qin H, et al.; Diabetic Retinopathy Clinical Research Network Writing Committee. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087–1093.
   PubMed Web of Science ®Google Scholar
• Song SJ, Sohn JH, Park KH. Evaluation of the efficacy of vitrectomy for persistent diabetic macular edema and associated factors predicting outcome. Korean J Ophthalmol. 2007;21:146–150.
   PubMedGoogle Scholar
• Nishijima K, Murakami T, Hirashima T, et al. Hyperreflective foci in outer retina predictive of photoreceptor damage and poor vision after vitrectomy for diabetic macular edema. Retina. 2014;34:732–740.
   PubMed Web of Science ®Google Scholar
• Chhablani JK, Kim JS, Cheng L, et al. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2012;250:1415–1420.
   PubMed Web of Science ®Google Scholar
• Ichiyama Y, Sawada O, Mori T, et al. The effectiveness of vitrectomy for diffuse diabetic macular edema may depend on its preoperative optical coherence tomography pattern. Graefes Arch Clin Exp Ophthalmol. 2016. Epub ahead of print.
   Web of Science ®Google Scholar
• Kojima T, Terasaki H, Nomura H, et al. Vitrectomy for diabetic macular edema: effect of glycemic control (HbA(1c)), renal function (creatinine) and other local factors. Ophthalmic Res. 2003;35:192–198.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Suzuma K, Ryu M, et al. Systemic factors influence the prognosis of diabetic macular edema after pars plana vitrectomy with internal limiting membrane peeling. Curr Eye Res. 2013;38:1261–1265.
   PubMed Web of Science ®Google Scholar
• Raizada S, Al Kandari J, Al Diab F, et al. Pars plana vitrectomy versus three intravitreal injections of bevacizumab for nontractional diabetic macular edema. A prospective, randomized comparative study. Indian J Ophthalmol. 2015;63:504–510.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31:915–923.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Tsuzuki A, Arai K, et al. Efficacy of intravitreal triamcinolone acetonide for diabetic macular edema after vitrectomy. J Ocul Pharmacol Ther. 2016;32:38–43.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Melia M, Glassman AR, et al. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina. 2015;35:2516–2528.
   PubMed Web of Science ®Google Scholar
• Sodhi A, Leung L-S, Do DV, et al. Recent trends in the management of rhegmatogenous retinal detachment. Surv Ophthalmol. 2008;53:50–67.
   PubMed Web of Science ®Google Scholar
• Morizane Y, Kimura S, Hosokawa M, et al. Planned foveal detachment technique for the resolution of diffuse diabetic macular edema. Jpn J Ophthalmol. 2015;59:279–287.
   PubMed Web of Science ®Google Scholar
• Tuuminen R, Sahanne S, Haukka J, et al. Improved outcome after primary vitrectomy in diabetic patients treated with statins. Eur J Ophthalmol. 2016;26:174–181.
   PubMedGoogle Scholar
• Diaz-Llopis M, Udaondo P, Millán JM, et al. Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4:319–323.
   PubMedGoogle Scholar
• de Smet MD, Gandorfer A, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial. Ophthalmology. 2009;116:1349–1355.
   PubMed Web of Science ®Google Scholar
• Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367:606–615.
   PubMed Web of Science ®Google Scholar
• Haller JA, Stalmans P, Benz MS, et al. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials. Ophthalmology. 2015;122:117–122.
   PubMed Web of Science ®Google Scholar
• Kim J, Kang SW, Shin DH, et al. Macular ischemia and outcome of vitrectomy for diabetic macular edema. Jpn J Ophthalmol. 2015;59:295–304.
   PubMed Web of Science ®Google Scholar